Ticker
ABIO

Price
2.34
Stock movement down
-0.08 (-3.30%)
Company name
ARCA Biopharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
33.72M
Ent verdi
-12.26M
Pris/omsetning
-
Pris/bok
0.70
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-24.52%
3 års avkastning
-25.19%
5 års avkastning
-34.76%
10 års avkastning
-37.49%
Sist oppdatert: 2022-08-25

UTBYTTE

ABIO betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok0.70
EV i forhold til salg-

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall14.41M
EPS (TTM)-1.28
FCF per aksje (TTM)-1.24

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-18.51M
Netto inntekt (TTM)-18.49M
EPS (TTM)-1.28
EPS (1 år fremover)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter49.06M
Netto fordringer0.00
Samlede omløpsmidler50.54M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler51.01M
Leverandørgjeld1.01M
Kortsiktig/nåværende langsiktig gjeld357.00K
Sum kortsiktig gjeld2.72M
Sum gjeld3.08M
Aksjonærenes egenkapital47.94M
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-17.84M
Kapitalutgifter (TTM)39.00K
Fri kontantstrøm (TTM)-17.87M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-38.58%
Avkastning på eiendeler-36.25%
Avkastning på investert kapital-38.58%
Kontantavkastning på investert kapital-37.29%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning2.38
Daglig høy2.42
Daglig lav2.31
Daglig volum48K
Tidenes høyeste5726700.00
1 år analytikerestimat7.00
Beta2.03
EPS (TTM)-1.28
Utbytte per aksje-
Ex-div dato1 May 2006
Neste dato for resultatpresentasjon31 Oct 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABIOS&P500
Nåværende prisfall fra toppnotering-100.00%-12.18%
Høyeste prisfall-100.00%-56.47%
Dato for høyeste fall25 Aug 20229 Mar 2009
Gj.snittlig fall fra topp-93.75%-11.38%
Gj.snittlig tid til ny topp274 days12 days
Maks tid til ny topp5666 days1805 days
SELSKAPSOPPLYSNINGER
ABIO (ARCA Biopharma Inc) company logo
Markedsverdi
33.72M
Markedsverdi kategori
Small-cap
Beskrivelse
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Ansatte
17
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Michael R. Bristow
Land
USA
By
Westminster
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIR...
2. august 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
18. juli 2022
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-We...
21. juni 2022
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 20...
5. mai 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE...
2. mai 2022
WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therap...
18. april 2022
Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with...
5. april 2022
ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized w...
1. april 2022
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reductio...
31. mars 2022
Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022WESTMINSTER, Colo., March 14, 2022 (GLOBE NEW...
14. mars 2022
Neste side